Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer Read more about Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer
A Study of Cell Therapy for Subjects With Acute Kidney Injury Who Are Receiving Continuous Renal Replacement Therapy Read more about A Study of Cell Therapy for Subjects With Acute Kidney Injury Who Are Receiving Continuous Renal Replacement Therapy
Needle-Guided vs Free-Hand Technique in Performing Brachial Plexus Blockade Read more about Needle-Guided vs Free-Hand Technique in Performing Brachial Plexus Blockade
Percutaneous HydroDiscectomy Compared to TESI for Radiculopathy Read more about Percutaneous HydroDiscectomy Compared to TESI for Radiculopathy
Risk Stratification After Acute Myocardial Infarction With Cardiac MRI Read more about Risk Stratification After Acute Myocardial Infarction With Cardiac MRI
Tolerization Reduces Intolerance to Pegloticase and Prolongs the Urate Lowering Effect Read more about Tolerization Reduces Intolerance to Pegloticase and Prolongs the Urate Lowering Effect
Safety and Efficacy Phase 3 Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient Children Read more about Safety and Efficacy Phase 3 Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient Children
Safety, Clinical Activity, Pharmacokinetics (PK) and Pharmacodynamics Study of GSK2879552, Alone or With Azacitidine, in Subjects With High Risk Myelodysplastic Syndromes (MDS) Read more about Safety, Clinical Activity, Pharmacokinetics (PK) and Pharmacodynamics Study of GSK2879552, Alone or With Azacitidine, in Subjects With High Risk Myelodysplastic Syndromes (MDS)
Dose Escalation and Expansion Study of GSK525762 in Combination With Fulvestrant in Participants With Hormone Receptor-positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Advanced or Metastatic Breast Cancer Read more about Dose Escalation and Expansion Study of GSK525762 in Combination With Fulvestrant in Participants With Hormone Receptor-positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Advanced or Metastatic Breast Cancer